TFF Pharmaceuticals Inc (FRA:0K30)

€ 8.91 0 (0%) Market Cap: 6.22 Mil Enterprise Value: 3.35 Mil PE Ratio: 0 PB Ratio: 1.03 GF Score: 29/100

TFF Pharmaceuticals Inc to Host Conference Call Transcript
Dec 19, 2023
Q3 2023 TFF Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2023

€4.98 (-1.49%)

Earnings
Q2 2023 TFF Pharmaceuticals Inc Earnings Call Transcript
Aug 15, 2023

€7.8 (-14.29%)

Earnings
TFF Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 09, 2023
TFF Pharmaceuticals Inc To Host Investor Call Transcript
Feb 16, 2023
Q3 2022 TFF Pharmaceuticals Inc Earnings Call Transcript
Nov 14, 2022

€62

Earnings
Q2 2022 TFF Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2022

€151.25 (+2.54%)

Earnings
Q1 2022 TFF Pharmaceuticals Inc Earnings Call Transcript
May 11, 2022

€98 (-1.51%)

Earnings
Q4 2021 TFF Pharmaceuticals Inc Earnings Call Transcript
Mar 24, 2022

€148.75 (+0.85%)

Earnings
TFF Pharmaceuticals Inc Science Day Transcript
Dec 13, 2021
Q3 2021 TFF Pharmaceuticals Inc Earnings Call Transcript
Nov 15, 2021

€156.25 (+0.81%)

Earnings
TFF Pharmaceuticals Inc Benzinga Global Small Cap Conference 2021 Transcript
Oct 29, 2021
TFF Pharmaceuticals Inc at SNN Network Summer Event (Virtual) Transcript
Aug 19, 2021
Q2 2021 TFF Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2021

€158.75

Earnings
Q1 2021 TFF Pharmaceuticals Inc Earnings Call Transcript
May 13, 2021

€185 (-1.33%)

Earnings

Q1 2022 TFF Pharmaceuticals Inc Earnings Call Transcript

May 11, 2022 / 08:30PM GMT

Release Date Price: €98 (-1.51%)

Transcript 10-Q8-K

Operator

Good day, and welcome to the TFF Pharmaceuticals, Inc. First Quarter 2020 Earnings Conference Call. (Operator Instructions) Please note this event is being recorded.

I would now like to turn the conference over to Corey Davis. Please go ahead.

Corey George Davis

LifeSci Advisors, LLC - Relationship Manager

Thank you, operator. Hello, everyone, and welcome to TFF Pharmaceuticals First Quarter Financial and Business Results Conference Call. With me on the line today is Glenn Mattes, President and CEO of TFF; Kirk Coleman, Chief Financial Officer; Dr. Dale Christensen, TFF's Director of Clinical Development; Dr. Bill Williams of the University of Texas at Austin; and Chris Cano, TFF's Chief Operating Officer.

Press release announcing our first quarter results is available on the TFF Pharmaceuticals website.

Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings release and this teleconference both include forward-looking statements. And these forward-looking statements are

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.